Nanomedicine for Drug Delivery Market Forecasts to 2030 – Global Analysis By Product Type (Nanoparticles, Nanoshells, Nanodevices and Nanotubes), Modality (Treatments and Diagnostics), Indication, Route of Administration, End User and By Geography

Nanomedicine for Drug Delivery Market Forecasts to 2030 – Global Analysis By Product Type (Nanoparticles, Nanoshells, Nanodevices and Nanotubes), Modality (Treatments and Diagnostics), Indication, Route of Administration, End User and By Geography

According to Stratistics MRC, the Global Nanomedicine for Drug Delivery Market is accounted for $197.6 billion in 2023 and is expected to reach $479.4 billion by 2030 growing at a CAGR of 13.5% during the forecast period. The field of medicine known as ""nanomedicine"" employs instruments and expertise in nanotechnology to prevent and cure various illnesses. Nanoparticles can be engineered to target specific cells or tissues, reducing side effects and increasing the drug's effectiveness by delivering it directly to the intended site. Nanoparticles can extend a drug's circulation time in the body, allowing for a sustained release of medication and reducing the frequency of dosing.

According to American Cancer Society, it is estimated in 2023, about 297,790 new cases of invasive breast cancer will be diagnosed in women in U.S. Nanoparticles, nanocarriers, and other nanoscale drug delivery platforms offer unique properties that enhance drug stability, solubility, bioavailability, and control over release kinetics.

Market Dynamics:

Driver:

Rising prevalence of chronic diseases

Chronic illnesses, including diabetes, heart disease, and cancer, are becoming more common. Nanomedicine-based drug delivery systems have shown promising results in improving the efficacy of therapeutic agents for these conditions. Treating chronic diseases has become more appealing for nanoparticles due to their capacity to target particular cells or tissues and deliver drugs directly to the site of action. The need for nanomedicine in drug delivery rises with the prevalence of these diseases.

Restraint:

Safety concerns

While nanomedicine offers numerous benefits, there are concerns regarding the safety of nanoparticles. Nanoparticles' small size and special physicochemical characteristics raise the possibility of unforeseen biological interactions and toxicity. The long-term effects of nanoparticle exposure and accumulation in the body are still being studied. The market's acceptance of nanomedicine products can be affected by safety concerns.

Opportunity:

Technological advancements in imaging and diagnostics

In diagnostic imaging methods like computed tomography (CT), positron emission tomography (PET), and magnetic resonance imaging (MRI), nanomedicine is essential. It is possible to engineer nanoparticles to carry imaging agents, improving disease detection and visualization. The integration of diagnostic and therapeutic functions in nanoparticles allows for theranostic applications, where diagnosis and treatment can be combined. The expansion of the nanomedicine drug delivery market has been facilitated by developments in imaging and diagnostics.

Threat:

Manufacturing scalability

Products involving nanomedicines can have complicated manufacturing processes requiring specialized facilities and machinery. There are many obstacles to overcome when increasing production while preserving the cost-effectiveness, consistency, and quality of the final product. The production of nanomedicine products frequently entails the complex and time-consuming processes of synthesizing, purifying, and characterizing nanoparticles. Advanced technologies and expertise are needed to produce nanoparticles with precise size, shape, and surface characteristics. Therefore, manufacturing scalability is a significant factor hampering market demand.

Covid-19 Impact

The COVID-19 pandemic profoundly affected the nanomedicine for drug delivery market. Disruptions in the global supply chain led to shortages of essential components, hindering the production of nanomedicine. Clinical trials for new applications faced delays or halts due to restrictions on in-person interactions, impacting research progress. Market demand fluctuated as the focus turned toward targeted drug delivery systems and remote healthcare solutions, highlighting the importance of adaptable and precise drug delivery mechanisms. The pandemic accelerated the adoption of telemedicine and remote patient monitoring, influencing the demand for drug delivery systems that support these new healthcare approaches.

The nanoshells segment is expected to be the largest during the forecast period

The nanoshells segment is estimated to hold the largest share. These are core-shell nanoparticles, with a thin metallic shell (usually made of silver or gold) encircling a dielectric core. Because of their special structure, their optical characteristics, namely, their capacity to scatter and absorb light, can be precisely controlled. Nanoshells are designed to carry and administer therapeutic agents to particular target areas within the body when it comes to drug delivery. It is possible to adjust their size and surface characteristics to maximize interactions with biological tissues. Additionally, they can also react to particular light wavelengths due to their metallic shell, which is an essential characteristic for targeted therapy and controlled drug release.

The oncological diseases segment is expected to have the highest CAGR during the forecast period

The oncological diseases segment is anticipated to have lucrative growth during the forecast period. They minimize damage to healthy tissues and enable precise targeting of tumors. By specifically recognizing and binding to cancer cells, these nanoparticles can be engineered to enhance the drug's accumulation at the tumor site. Furthermore, these nanocarriers' special qualities allow for regulated drug release, resulting in long-lasting and targeted therapeutic effects. Because of their small size, they can penetrate tumor tissues and reach places that may be difficult for conventional medications to reach.

Region with largest share:

North America commanded the largest market share during the extrapolated period. Significant investments in research and development, in conjunction with a strong healthcare system, create an atmosphere that is favourable to innovative developments in nanotechnology. Leading biotech and pharmaceutical companies is present, which encourages teamwork and leads to the development of advanced drug delivery systems. Establishing a culture of innovation and discovery, academic institutions and research centers consistently contribute to technological breakthroughs in nanomedicine in this region.

Region with highest CAGR:

Europe is expected to witness profitable growth over the projection period, owing to its strong focus on research and development, Europe is a prominent hub for nanomedicine in drug delivery. This innovation is driven by nations like Germany, the UK, and Switzerland, which provide a rich environment for scientific research and technological development. The region is focused on cutting-edge methods, with a particular emphasis on precision medicine and customized treatments utilizing nanotechnology. Europe as a driving force in the evolution of advanced drug delivery systems, making it a crucial player in the global nanomedicine market.

Key players in the market

Some of the key players in the Nanomedicine for Drug Delivery Market include Camurus AB, Celgene, Inc., Eye Point Pharmaceuticals, EnColl Corporation, Cytimmune Sciences, Inc., Ceramisphere Health Pty Limited, Cristal Therapeutics, Aquanova AG, Blue Willow Biologics, AbbVie Inc., Amgen Foundation, Abbott, Cadila Pharmaceuticals , Novartis AG, Johnson & Johnson Services, Pfizer Inc., F. Hoffmann-La Roche Ltd and Eli Lilly and Company.

Key Developments:

In Dec 2022, Eli Lilly and Company and EVA Pharma announced a collaboration to deliver a sustainable supply of high-quality, affordable human and analogue insulin to at least one million people living with type 1 and type 2 diabetes in low-to middle income.

In Aug 2022, Abbott and WeightWatchers announced a strategic partnership that will help people living with diabetes better understand and manage their diabetes and weight.

In June 2022, Pfizer announces Strategic Collaboration with Truveta to Accelerate Safety Insights in Real Time. Truveta will provide Pfizer with an unprecedented data platform for research. The data collected by Truveta are always flowing, providing the most up-to-date picture of U.S. health.

Product Types Covered:
• Nanoparticles
• Nanoshells
• Nanodevices
• Nanotubes

Modalities Covered:
• Treatments
• Diagnostics

Indications Covered:
• Infectious Diseases
• Orthopedic Disorders
• Oncological Diseases
• Cardiovascular Diseases
• Urological Diseases
• Neurological Diseases
• Immunological Diseases
• Ophthalmological Diseases
• Other Indications

Route of Administrations Covered:
• Parenteral
• Oral
• Inhalation
• Topical

End Users Covered:
• Specialty Clinics
• Hospitals
• Other End Users

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements